Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Maintenance Therapy : Revlimid vs. Revlimid + Dara | AURIGA Update| Larry Anderson, MD, PhD | #ims25
HealthTreeDescription
In this video, Dr. Larry Anderson shares the latest findings from the AURIGA clinical trial, comparing maintenance therapy with Revlimid (lenalidomide) alone versus Revlimid plus Daratumumab in multiple myeloma.
Learn how these updated results may impact treatment decisions, progression-free survival, and the future of maintenance therapy in myeloma. This important discussion from #IMS2025 highlights how adding daratumumab to standard Revlimid maintenance could improve outcomes for patients after initial therapy.
If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu
For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.